Price Alert

Editas Medicine Inc. (EDIT)

NASDAQ: EDIT · Real-Time Price · USD

3.85

-0.04 (-1.03%)

At close: Oct 03, 2025, 2:30 PM

-1.03% (1D)

Bid	3.85
Market Cap	346.19M
Revenue (ttm)	38.9M
Net Income (ttm)	-236.86M
EPS (ttm)	-2.91
PE Ratio (ttm)	-1.32
Forward PE	-3.26
Analyst	Hold
Dividends	n/a

Ask	3.86
Volume	2,727,651
Avg. Volume (20D)	2,322,573
Open	3.97
Previous Close	3.89
Day's Range	3.77 - 4.05
52-Week Range	0.91 - 4.05
Beta	2.18
Ex-Dividend Date	n/a

About EDIT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EDIT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EDIT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Editas Medicine Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+34.5%

Editas Medicine shares are trading higher after th... Unlock content with Pro Subscription

9 months ago

-23.81%

Editas Medicine shares are trading lower after Stifel and Chardan Capital downgraded the stock and multiple firms cut their respective price targets.

News

3 weeks ago · zacks.com

Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

4 weeks ago · zacks.com

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

1 month ago · seekingalpha.com

Editas Medicine, Inc. - Special Call

Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - R...

1 month ago · fool.com

Why Editas Medicine Stock Was Skyrocketing This Week

Gene-editing company Editas Medicine (EDIT -4.06%) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34%...

1 month ago · zacks.com

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago.